MCID: CRV038
MIFTS: 57

Cervical Squamous Cell Carcinoma

Categories: Reproductive diseases, Rare diseases, Cancer diseases

Aliases & Classifications for Cervical Squamous Cell Carcinoma

MalaCards integrated aliases for Cervical Squamous Cell Carcinoma:

Name: Cervical Squamous Cell Carcinoma 38 12 56 52 14 69
Squamous Cell Carcinoma of the Cervix Uteri 12 56
Squamous Cell Carcinoma of Cervix 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3744
NCIt 47 C4028
SNOMED-CT 64 254886006
Orphanet 56 ORPHA213767
UMLS via Orphanet 70 C0279671
ICD10 via Orphanet 34 C53.0 C53.1 C53.8
UMLS 69 C0279671

Summaries for Cervical Squamous Cell Carcinoma

Disease Ontology : 12 A cervix carcinoma that has material basis in squamous cells of the cervix.

MalaCards based summary : Cervical Squamous Cell Carcinoma, also known as squamous cell carcinoma of the cervix uteri, is related to microinvasive cervical squamous cell carcinoma and cervical intraepithelial neoplasia. An important gene associated with Cervical Squamous Cell Carcinoma is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are MicroRNAs in cancer and DNA Damage. The drugs Cetuximab and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include cervix, uterus and lung, and related phenotypes are Decreased viability and cellular

Related Diseases for Cervical Squamous Cell Carcinoma

Diseases related to Cervical Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 132)
id Related Disease Score Top Affiliating Genes
1 microinvasive cervical squamous cell carcinoma 12.2
2 cervical intraepithelial neoplasia 11.4
3 cervicitis 11.0
4 squamous cell carcinoma 11.0
5 cervical adenoid cystic carcinoma 10.8 CDKN2A TP53
6 renal pelvis urothelial papilloma 10.8 CDH1 TP53
7 myeloid/lymphoid neoplasm associated with pdgfra rearrangement 10.7 CDKN2A EGFR
8 leiomyoma cutis 10.7 CDKN2A TP53
9 amelogenesis imperfecta local hypoplastic 10.7 CDKN2A MKI67 TP63
10 anal squamous cell carcinoma 10.7 CDKN2A TP53
11 split hand split foot nystagmus 10.7 CDKN2A MKI67 TP53
12 malignant giant cell tumor of soft parts 10.7 CDKN2A EGFR
13 orbital lymphoma 10.7 CDKN2A MKI67 TP53
14 rectum squamous cell carcinoma 10.6 CDKN2A TP53
15 breast myoepitheliosis 10.6 CDKN2A TP53
16 gastrointestinal neuroendocrine tumor 10.6 CDH1 CDKN2A TP53
17 childhood oligodendroglioma 10.6 CDKN2A MKI67 TP53
18 pediatric infratentorial ependymoma 10.6 EGFR MKI67 TP53
19 ritter's disease 10.6 CDKN2A TP53
20 tracheal disease 10.6 CDH1 CDKN2A TP53
21 hypogonadotropic hypogonadism-retinitis pigmentosa syndrome 10.6 EGFR TP53
22 hodgkin's lymphoma, mixed cellularity 10.6 CDH1 CDKN2A TP53
23 reese retinal dysplasia 10.6 EGFR HLA-DRB1
24 cecum adenocarcinoma 10.6 CDKN2A EGFR TP53
25 myxedema 10.6 CDKN2A EGFR TP53
26 sparse hair ptosis mental retardation 10.6 EGFR MKI67 TP53
27 bladder colloid adenocarcinoma 10.6 CDKN2A MKI67
28 c-p angle neurinoma 10.6 CDKN2A SOX2 TP53
29 cystic lymphangioma 10.6 CDKN2A EGFR TP53
30 lacrimal gland mucoepidermoid carcinoma 10.6 CDH1 EGFR TP53
31 benign shuddering attacks 10.6 CDH1 CDKN2A TP53
32 coccidiosis 10.5 CDKN2A SERPINB3 TP53
33 camptocormism 10.5 KRT8 TP53
34 post-surgical hypoinsulinemia 10.5 CDKN2A SOX2 TP53
35 arteritic anterior ischemic optic neuropathy 10.5 CDH1 EGFR TP53
36 mesothelioma, somatic 10.5 CDH1 CDKN2A RASSF1
37 esophagus squamous cell carcinoma 10.5 CDKN2A SERPINB3 TP53
38 spindle epithelial tumor with thymus-like differentiation tumor 10.5 CDKN2A EGFR SERPINB3
39 nasopharyngeal carcinoma 10.5 CDKN2A EGFR TP53
40 apocrine adenocarcinoma 10.5 CDH1 EGFR TP53
41 bladder urachal squamous cell carcinoma 10.5 CDKN2A EGFR TP53
42 pseudounicornuate uterus 10.5 MKI67 TP63
43 plasmodium ovale malaria 10.5 CDKN2A MKI67 TP53 TP63
44 spinal cord glioma 10.5 CDKN2A EGFR TP53
45 bladder squamous cell carcinoma 10.5 CDKN2A TP53 TYMP
46 childhood infratentorial neoplasm 10.5 EGFR TP53
47 choriocarcinoma 10.4 CDKN2A TP53 TYMP
48 cleft lip palate dysmorphism kumar type 10.4 EGFR RASSF1 TP53
49 pancreatic serous cystic neoplasm 10.4 EGFR SOX2 TP53
50 pancreatic somatostatinoma 10.4 CDH1 CDKN2A EGFR TP53

Graphical network of the top 20 diseases related to Cervical Squamous Cell Carcinoma:



Diseases related to Cervical Squamous Cell Carcinoma

Symptoms & Phenotypes for Cervical Squamous Cell Carcinoma

GenomeRNAi Phenotypes related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.47 DAPK1 EGFR
2 Decreased viability GR00221-A-1 9.47 CDH1 CDKN2A DAPK1 EGFR SOX2
3 Decreased viability GR00221-A-3 9.47 CDKN2A
4 Decreased viability GR00221-A-4 9.47 CDKN2A DAPK1 EGFR SOX2
5 Decreased viability GR00301-A 9.47 CDH1
6 Decreased viability GR00342-S-1 9.47 DAPK1

MGI Mouse Phenotypes related to Cervical Squamous Cell Carcinoma:

44 (show all 11)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.24 CDH1 CDKN2A DAPK1 EGFR KRT17 RASSF1
2 homeostasis/metabolism MP:0005376 10.21 CDH1 CDKN2A DAPK1 EGFR KRT8 OSMR
3 immune system MP:0005387 10.14 CDH1 CDKN2A EGFR KRT8 OSMR RASSF1
4 digestive/alimentary MP:0005381 10.13 CDH1 CDKN2A EGFR KRT17 KRT8 RASSF1
5 endocrine/exocrine gland MP:0005379 10.11 CDH1 CDKN2A EGFR OSMR RASSF1 SKP2
6 integument MP:0010771 9.97 CDH1 CDKN2A EGFR KRT17 OSMR SOX2
7 liver/biliary system MP:0005370 9.87 CDKN2A EGFR KRT8 OSMR RASSF1 SKP2
8 neoplasm MP:0002006 9.8 CDKN2A EGFR RASSF1 SOX2 TP53 TP63
9 no phenotypic analysis MP:0003012 9.76 CDH1 CDKN2A EGFR KRT17 OSMR SOX2
10 pigmentation MP:0001186 9.35 CDKN2A EGFR KRT17 SOX2 TP53
11 reproductive system MP:0005389 9.23 CDH1 CDKN2A EGFR KRT8 SKP2 SOX2

Drugs & Therapeutics for Cervical Squamous Cell Carcinoma

Drugs for Cervical Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 458)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cetuximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 205923-56-4 56842117 2333
2
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
3
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 84093 441203 2767
4
Cevimeline Approved Phase 4,Phase 3 107233-08-9 83898 25137844
5
Ethanol Approved Phase 4,Phase 1 64-17-5 702
6
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 184475-35-2 123631
7
Petrolatum Approved Phase 4 8009-03-8
8 Titanium dioxide Approved Phase 4 13463-67-7
9
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
10
Morphine Approved, Investigational Phase 4 57-27-2 5288826
11
Raltitrexed Approved, Investigational Phase 4,Phase 3 112887-68-0 104758
12
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
13
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 143 6006
14
Docetaxel Approved May 1996, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 114977-28-5 148124 9877265
15 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
16 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
17 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
18 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
20 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Mitomycins Phase 4,Phase 3,Phase 2
22 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
23 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
24 Cholinergic Agents Phase 4,Phase 3
25 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
26 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
27 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 Anti-Inflammatory Agents Phase 4,Phase 1,Phase 2,Early Phase 1
29 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Analgesics Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
31 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1
33 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1
34 Epoetin alfa Phase 4,Phase 3,Phase 2 113427-24-0
35 Hematinics Phase 4,Phase 3,Phase 2,Early Phase 1
36 Anesthetics Phase 4,Phase 3,Phase 2
37 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Early Phase 1
38 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Anti-Allergic Agents Phase 4,Phase 2
40 mometasone furoate Phase 4 83919-23-7
41 Adjuvants, Anesthesia Phase 4
42 Analgesics, Opioid Phase 4,Phase 2
43 Anesthetics, General Phase 4
44 Anesthetics, Intravenous Phase 4
45 Narcotics Phase 4,Phase 2
46 Folate Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
47 Vitamin B9 Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
48 arginine Nutraceutical Phase 4,Phase 2,Phase 1
49 Omega 3 Fatty Acid Nutraceutical Phase 4,Phase 2,Phase 1
50
Epinephrine Approved, Vet_approved Phase 3,Phase 2 51-43-4 5816

Interventional clinical trials:

(show top 50) (show all 1178)

id Name Status NCT ID Phase Drugs
1 Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and Neck Unknown status NCT02015650 Phase 4 Cetuximab;Mitomycin-C/ 5-Fluorouracil
2 Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE) Unknown status NCT01553032 Phase 4 Erbitux®
3 Epoetin Beta in Treating Anemia in Patients With Cervical Cancer Completed NCT00046969 Phase 4 cisplatin
4 Study of the Effectiveness of Cevimeline on Oral Health in Patients With Radiation Induced Xerostomia Completed NCT00466388 Phase 4 Cevimeline
5 Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy Completed NCT02972216 Phase 4 Nolbaxol;Taxotere;cisplatin
6 Efficacy of Chemoradiotherapy After Neoadjuvant Cisplatin and Docetaxel in the Nasopharynx Carcinoma Completed NCT00772681 Phase 4 docetaxel and cisplatin
7 Comparison of Two Immunomodulatory Formulas on the Number of Postoperative Infections in Head & Neck Cancer Patients Completed NCT02622880 Phase 4
8 Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients Recruiting NCT02495064 Phase 4 Mometasone Furoate Cream
9 Analgesic Efficacy of Transmucosal Fentanyl for Breakthrough Pain Caused by Interventional Gastrostomy Recruiting NCT02869321 Phase 4 Fentanyl;Morphine Sulfate;Fentanyl placebo;Morphine Sulfate placebo
10 An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck Active, not recruiting NCT00684385 Phase 4 ZD1839
11 Stereotactic Body Radiotherapy for Head and Neck Tumors Active, not recruiting NCT01344356 Phase 4
12 Radiotherapy Combine With Raltitrexed Versus Radiotherapy Alone in Older Patients With HNSCC. Not yet recruiting NCT03196843 Phase 4 Raltitrexed
13 Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status NCT00002659 Phase 3 cisplatin-e therapeutic implant
14 S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer Unknown status NCT00336947 Phase 3 tegafur-gimeracil-oteracil potassium;tegafur-uracil
15 Evaluation of 3DCRT Versus IGRT and Analysis of Early Response in Head and Neck Cancer. Unknown status NCT01124409 Phase 3
16 Double-blind, Placebo-controlled, Randomized Study of the Effectiveness of Escitalopram on Emotional Distress of Head and Neck Cancer Patients During Cancer Treatment Unknown status NCT00935675 Phase 3 Escitalopram
17 Surgery and Radiation Therapy With or Without Chemotherapy in Treating Patients With Mouth Cancer Unknown status NCT00002747 Phase 3 cisplatin;fluorouracil
18 Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate Unknown status NCT00041613 Phase 3
19 Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone Unknown status NCT00041626 Phase 3
20 Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx Unknown status NCT00002702 Phase 3
21 Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Advanced Cancer of the Oropharynx or Hypopharynx Unknown status NCT00003627 Phase 3 cisplatin;fluorouracil
22 Topical Imiquimod for Bowen's Disease of the Head and Neck Unknown status NCT00384124 Phase 2, Phase 3 Imiquimod
23 Oral Cancer Adjuvant Therapy (OCAT) Trial Unknown status NCT00193843 Phase 3
24 Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer Unknown status NCT01074021 Phase 3 Nimotuzumab;placebo plus chemoradiotherapy
25 PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck Cancer Unknown status NCT00720070 Phase 3
26 Radiation Therapy Alone Compared to Radiation Therapy Plus Chemotherapy in Treating Patients With Previously Untreated Cancer of the Nasopharynx Unknown status NCT00003637 Phase 3 cisplatin;fluorouracil
27 Comparison of Three Chemotherapy Regimens in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed NCT00003945 Phase 3 cisplatin;topotecan hydrochloride
28 Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck Completed NCT00442455 Phase 3 Erlotinib chlorhydrate;Cisplatin
29 Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects Completed NCT01012258 Phase 3
30 A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck Completed NCT01177956 Phase 3 Cisplatin;5-Fluorouracil
31 Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Completed NCT01086826 Phase 3 RT+CDDP/5-FU;RT+CETUXIMAB;INDUCTION CTx(TPF)+(RT+CDDP/5-FU);INDUCTION CTx(TPF)+(RT+CETUXIMAB)
32 Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX) Completed NCT00206219 Phase 3 Gefitinib;methotrexate
33 Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed NCT00803062 Phase 3 Cisplatin;Paclitaxel;Topotecan Hydrochloride
34 Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Completed NCT00064077 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Paclitaxel;Topotecan Hydrochloride;Vinorelbine Tartrate
35 Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME) Completed NCT00122460 Phase 3 Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU);Platinum (Cisplatin or Carboplatin) + 5-FU
36 Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Completed NCT00401323 Phase 2, Phase 3 docetaxel (XRP6976);cisplatin;5-fluorouracil (5-FU)
37 LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy Completed NCT01345682 Phase 3 Afatinib;Methotrexate
38 Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck Completed NCT00771641 Phase 3
39 DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC Completed NCT00496652 Phase 3 Zalutumumab
40 Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers Completed NCT01166542 Phase 3 Carboplatin;Paclitaxel;Placebo
41 Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer Completed NCT00460265 Phase 3 ARM 2;ARM 1
42 Radiation Therapy With or Without Chemotherapy After Surgery in Treating Patients With Stage IB or Stage IIA Cervical Cancer Completed NCT00003209 Phase 3 cisplatin;fluorouracil;ifosfamide;methotrexate;mitomycin C;vinblastine sulfate;vindesine
43 Radiation Therapy in Treating Patients With Metastases to the Lymph Nodes in the Neck From an Unknown Primary Tumor Completed NCT00047125 Phase 3
44 Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia Completed NCT00017004 Phase 3 Cisplatin
45 Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00054561 Phase 3 isotretinoin
46 Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003592 Phase 3 methotrexate;paclitaxel
47 Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During Surgery Completed NCT00002670 Phase 3 chemotherapy;cisplatin
48 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003888 Phase 3 cisplatin;docetaxel;fluorouracil
49 Radiation Therapy With or Without Cisplatin or Fluorouracil in Treating Patients With Cancer of the Cervix Completed NCT00003078 Phase 3 cisplatin;fluorouracil
50 Radiation Therapy and Cisplatin or Panitumumab in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer Completed NCT00820248 Phase 3 cisplatin

Search NIH Clinical Center for Cervical Squamous Cell Carcinoma

Genetic Tests for Cervical Squamous Cell Carcinoma

Anatomical Context for Cervical Squamous Cell Carcinoma

MalaCards organs/tissues related to Cervical Squamous Cell Carcinoma:

39
Cervix, Uterus, Lung, Lymph Node, Breast, Skin, Brain

Publications for Cervical Squamous Cell Carcinoma

Articles related to Cervical Squamous Cell Carcinoma:

(show top 50) (show all 322)
id Title Authors Year
1
Association of Casp3 microRNA Target Site (1049216) SNP With the Risk and Progress of Cervical Squamous Cell Carcinoma. ( 28114230 )
2017
2
Correlation Between Squamous Cell Carcinoma Antigen Level and the Clinicopathological Features of Early-Stage Cervical Squamous Cell Carcinoma and the Predictive Value of Squamous Cell Carcinoma Antigen Combined With Computed Tomography Scan for Lymph Node Metastasis. ( 28914639 )
2017
3
Fatty acid binding protein 4 promotes epithelial-mesenchymal transition in cervical squamous cell carcinoma through AKT/GSK3I^/Snail signaling pathway. ( 28893569 )
2017
4
Characterization of the microRNA profile in early-stage cervical squamous cell carcinoma by next-generation sequencing. ( 28098890 )
2017
5
Associations between intratumoral and peritumoral M2 macrophage counts and cervical squamous cell carcinoma invasion patterns. ( 28884821 )
2017
6
Bioinformatics and in vitro experimental analyses identify the selective therapeutic potential of interferon gamma and apigenin against cervical squamous cell carcinoma and adenocarcinoma. ( 28526810 )
2017
7
Aurora-A affects radiosenstivity in cervical squamous cell carcinoma and predicts poor prognosis. ( 28404933 )
2017
8
Proteomic identification of potential biomarkers for cervical squamous cell carcinoma and human papillomavirus infection. ( 28443473 )
2017
9
Expression of Estrogen and Progesterone Receptor in Tumor Stroma Predicts Favorable Prognosis of Cervical Squamous Cell Carcinoma. ( 28472813 )
2017
10
Serum MicroRNAs Related with Chemoradiotherapy Resistance in Advanced-Stage Cervical Squamous Cell Carcinoma. ( 28432899 )
2017
11
Chondrosarcoma-like metastasis from a poorly differentiated uterine cervical squamous cell carcinoma. A unique morphology and diagnostic pitfall in cytology. ( 28411397 )
2017
12
Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status. ( 28833798 )
2017
13
Sulfiredoxin may promote metastasis and invasion of cervical squamous cell carcinoma by epithelial-mesenchymal transition. ( 28351308 )
2017
14
Early vulvar and umbilical incisional scar recurrence of cervical squamous cell carcinoma: Earlier than usually expected. ( 28913152 )
2017
15
Radiation therapy versus surgery for patients with cervical squamous cell carcinoma who have undergone neoadjuvant chemotherapy revisited. ( 28929314 )
2017
16
Short interfering RNA targeting Net1 reduces the angiogenesis and tumor growth of in vivo cervical squamous cell carcinoma through VEGF down-regulation. ( 28511963 )
2017
17
The Prognosis and Risk Stratification Based on Pelvic Lymph Node Characteristics in Patients With Locally Advanced Cervical Squamous Cell Carcinoma Treated With Concurrent Chemoradiotherapy. ( 27400321 )
2016
18
Functional significance of transgelin-2 in uterine cervical squamous cell carcinoma. ( 26891454 )
2016
19
Scalp Metastasis as a Presenting Symptom of Cervical Squamous Cell Carcinoma. ( 27105328 )
2016
20
Biventricular metastatic invasion from cervical squamous cell carcinoma. ( 27371746 )
2016
21
Integrative genomic and network analysis identified novel genes associated with the development of advanced cervical squamous cell carcinoma. ( 27641506 )
2016
22
High Expression of KIF20A Is Associated with Poor Overall Survival and Tumor Progression in Early-Stage Cervical Squamous Cell Carcinoma. ( 27941992 )
2016
23
TRPV6 is a prognostic marker in early-stage cervical squamous cell carcinoma. ( 27747588 )
2016
24
Expression of E-, P- and N-Cadherin and Its Clinical Significance in Cervical Squamous Cell Carcinoma and Precancerous Lesions. ( 27223886 )
2016
25
Acrokeratosis Paraneoplastica Associated with Cervical Squamous Cell Carcinoma. ( 28101384 )
2016
26
5-Hydroxymethylcytosine expression is associated with poor survival in cervical squamous cell carcinoma. ( 26851753 )
2016
27
I9Np63I+ attenuates tumor aggressiveness by suppressing miR-205/ZEB1-mediated epithelial-mesenchymal transition in cervical squamous cell carcinoma. ( 26864590 )
2016
28
DEPTOR promotes survival of cervical squamous cell carcinoma cells and its silencing induces apoptosis through downregulating PI3K/AKT and by up-regulating p38 MAP kinase. ( 26992219 )
2016
29
A comprehensive expression analysis of the MIA gene family in malignancies: MIA gene family members are novel, useful markers of esophageal, lung, and cervical squamous cell carcinoma. ( 27145272 )
2016
30
ITPR3 gene haplotype is associated with cervical squamous cell carcinoma risk in Taiwanese women. ( 28036301 )
2016
31
The Value of Diffusion-Weighted Imaging in Predicting the Prognosis of Stage IB-IIA Cervical Squamous Cell Carcinoma After Radical Hysterectomy. ( 26807567 )
2016
32
Functional variant of the P2X7 receptor gene is associated with human papillomavirus-16 positive cervical squamous cell carcinoma. ( 27779103 )
2016
33
Prognostic Value of Neutrophil-Related Factors in Locally Advanced Cervical Squamous Cell Carcinoma Patients Treated with Cisplatin-Based Concurrent Chemoradiotherapy. ( 27087737 )
2016
34
A retrospective study of neoadjuvant chemotherapy plus radical hysterectomy versus radical hysterectomy alone in patients with stage II cervical squamous cell carcinoma presenting as a bulky mass. ( 27695343 )
2016
35
Expression of HIF-2I+ and VEGF in Cervical Squamous Cell Carcinoma and Its Clinical Significance. ( 27413748 )
2016
36
Increased expression of long non-coding RNA XIST predicts favorable prognosis of cervical squamous cell carcinoma subsequent to definitive chemoradiation therapy. ( 27899965 )
2016
37
Vasculogenic mimicry and hypoxia-inducible factor-1I+ expression in cervical squamous cell carcinoma. ( 26985936 )
2016
38
Efficacy of neoadjuvant chemotherapy plus radical surgery in patients with bulky stage II cervical squamous cell carcinoma: A retrospective cohort study. ( 27131759 )
2016
39
Potential impact of mTOR inhibitors on cervical squamous cell carcinoma: A systematic review. ( 27895779 )
2016
40
Prognostic Significance of Cytokeratin 19 and Squamous Cell Cancer Antigen in Histologically Negative Sentinel Lymph Nodes of Cervical Squamous Cell Carcinoma. ( 27654256 )
2016
41
Role of difucosylated Lewis Y antigen in outcome of locally advanced cervical squamous cell carcinoma treated with cisplatin regimen. ( 27197582 )
2016
42
UHRF1 gene silencing inhibits cell proliferation and promotes cell apoptosis in human cervical squamous cell carcinoma CaSki cells. ( 27431502 )
2016
43
MRI in the synchronic chemoradiotherapy of cervical squamous cell carcinoma. ( 27352568 )
2016
44
Overexpression of the oncostatin-M receptor in cervical squamous cell carcinoma is associated with epithelial-mesenchymal transition and poor overall survival. ( 27351213 )
2016
45
Involvement of myeloperoxidase gene polymorphism 463G>A in development of cervical squamous cell carcinoma. ( 27197583 )
2016
46
Increased RIPK4 expression is associated with progression and poor prognosis in cervical squamous cell carcinoma patients. ( 26148476 )
2015
47
Therapeutic effects of antibiotic drug tigecycline against cervical squamous cell carcinoma by inhibiting Wnt/I^-catenin signaling. ( 26427870 )
2015
48
Putative stem cell markers in cervical squamous cell carcinoma are correlated with poor clinical outcome. ( 26499463 )
2015
49
Sex-determining region Y-related high mobility group box (SOX)-2 is overexpressed in cervical squamous cell carcinoma and contributes cervical cancer cell migration and invasion in vitro. ( 25935536 )
2015
50
Expressions and clinical significance of autophagy-related markers Beclin1, LC3, and EGFR in human cervical squamous cell carcinoma. ( 26346666 )
2015

Variations for Cervical Squamous Cell Carcinoma

Cosmic variations for Cervical Squamous Cell Carcinoma:

9 (show top 50) (show all 57)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM43896 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.818G>C p.R273P 12
2 COSM43662 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.868C>A p.R290S 12
3 COSM10662 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 12
4 COSM10659 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.817C>T p.R273C 12
5 COSM44029 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.550G>A p.D184N 12
6 COSM45259 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.301A>T p.K101* 12
7 COSM43660 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.719G>T p.S240I 12
8 COSM11483 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.848G>A p.R283H 12
9 COSM10705 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.586C>T p.R196* 12
10 COSM10648 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.524G>A p.R175H 12
11 COSM45507 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.806G>C p.S269T 12
12 COSM10725 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.701A>G p.Y234C 12
13 COSM11356 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.726C>G p.C242W 12
14 COSM46185 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.775G>C p.D259H 12
15 COSM10889 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.536A>G p.H179R 12
16 COSM43878 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.427G>A p.V143M 12
17 COSM43624 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.875A>G p.K292R 12
18 COSM10749 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.830G>T p.C277F 12
19 COSM25844 STK11 cervix,NS,carcinoma,squamous cell carcinoma c.647C>T p.S216F 12
20 COSM29465 STK11 cervix,NS,carcinoma,squamous cell carcinoma c.320A>G p.H107R 12
21 COSM3734673 STK11 cervix,NS,carcinoma,squamous cell carcinoma c.597G>C p.E199D 12
22 COSM29464 STK11 cervix,NS,carcinoma,squamous cell carcinoma c.169G>T p.E57* 12
23 COSM5089 PTEN cervix,NS,carcinoma,squamous cell carcinoma c.517C>T p.R173C 12
24 COSM5945791 PTEN cervix,NS,carcinoma,squamous cell carcinoma c.65A>G p.D22G 12
25 COSM5878662 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1579G>A p.D527N 12
26 COSM12459 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1637A>G p.Q546R 12
27 COSM760 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1624G>A p.E542K 12
28 COSM773 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.3129G>T p.M1043I 12
29 COSM12458 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1634A>C p.E545A 12
30 COSM763 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1633G>A p.E545K 12
31 COSM766 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1636C>A p.Q546K 12
32 COSM775 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.3140A>G p.H1047R 12
33 COSM17442 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1624G>C p.E542Q 12
34 COSM1168056 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.3145G>T p.G1049C 12
35 COSM580 NRAS cervix,NS,carcinoma,squamous cell carcinoma c.181C>A p.Q61K 12
36 COSM120958 NFE2L2 cervix,NS,carcinoma,squamous cell carcinoma c.235G>C p.E79Q 12
37 COSM521 KRAS cervix,NS,carcinoma,squamous cell carcinoma c.35G>A p.G12D 12
38 COSM517 KRAS cervix,NS,carcinoma,squamous cell carcinoma c.34G>A p.G12S 12
39 COSM518 KRAS cervix,NS,carcinoma,squamous cell carcinoma c.34G>C p.G12R 12
40 COSM551 KRAS cervix,NS,carcinoma,squamous cell carcinoma c.182A>C p.Q61P 12
41 COSM555 KRAS cervix,NS,carcinoma,squamous cell carcinoma c.183A>T p.Q61H 12
42 COSM552 KRAS cervix,NS,carcinoma,squamous cell carcinoma c.182A>G p.Q61R 12
43 COSM483 HRAS cervix,NS,carcinoma,squamous cell carcinoma c.35G>T p.G12V 12
44 COSM480 HRAS cervix,NS,carcinoma,squamous cell carcinoma c.34G>A p.G12S 12
45 COSM497 HRAS cervix,NS,carcinoma,squamous cell carcinoma c.181C>G p.Q61E 12
46 COSM499 HRAS cervix,NS,carcinoma,squamous cell carcinoma c.182A>G p.Q61R 12
47 COSM715 FGFR3 cervix,NS,carcinoma,squamous cell carcinoma c.746C>G p.S249C 12
48 COSM49174 FGFR2 cervix,NS,carcinoma,squamous cell carcinoma c.289G>A p.A97T 12
49 COSM49175 FGFR2 cervix,NS,carcinoma,squamous cell carcinoma c.1976A>T p.K659M 12
50 COSM5730 CTNNB1 cervix,NS,carcinoma,squamous cell carcinoma c.122C>A p.T41N 12

Copy number variations for Cervical Squamous Cell Carcinoma from CNVD:

7 (show all 38)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 191444 5 1 15100000 Gain PDCD6 Cervical squamous cell carcinoma
2 191466 5 1 18500000 Gain POLS Cervical squamous cell carcinoma
3 191467 5 1 18500000 Gain SDHA Cervical squamous cell carcinoma
4 191468 5 1 18500000 Gain SRD5A1 Cervical squamous cell carcinoma
5 191624 5 1 42400000 Gain RPL37 Cervical squamous cell carcinoma
6 191625 5 1 42400000 Gain SKP2 Cervical squamous cell carcinoma
7 191627 5 1 42400000 Gain SLC1A3 Cervical squamous cell carcinoma
8 191642 5 1 4400000 Gain IRX2 Cervical squamous cell carcinoma
9 191643 5 1 4400000 Gain NDUFS6 Cervical squamous cell carcinoma
10 191644 5 1 4400000 Gain TERT Cervical squamous cell carcinoma
11 191646 5 1 4400000 Gain TRIP13 Cervical squamous cell carcinoma
12 191726 5 1 8200000 Gain IRX4 Cervical squamous cell carcinoma
13 195451 5 15100000 18500000 Gain ANKH Cervical squamous cell carcinoma
14 195452 5 15100000 18500000 Gain ZNF622 Cervical squamous cell carcinoma
15 195453 5 15100000 23300000 Gain MYO10 Cervical squamous cell carcinoma
16 195454 5 15100000 29300000 Gain BASP1 Cervical squamous cell carcinoma
17 198725 5 29300000 34400000 Gain DROSHA Cervical squamous cell carcinoma
18 198726 5 29300000 34400000 Gain GOLPH3 Cervical squamous cell carcinoma
19 198727 5 29300000 34400000 Gain MTMR12 Cervical squamous cell carcinoma
20 198728 5 29300000 34400000 Gain SUB1 Cervical squamous cell carcinoma
21 199076 5 34400000 38500000 Gain DNAJA5 Cervical squamous cell carcinoma
22 199078 5 34400000 38500000 Gain LMBRD2 Cervical squamous cell carcinoma
23 199079 5 34400000 38500000 Gain NIPBL Cervical squamous cell carcinoma
24 199080 5 34400000 38500000 Gain RAD1 Cervical squamous cell carcinoma
25 199082 5 34400000 38500000 Gain TARS Cervical squamous cell carcinoma
26 199083 5 34400000 38500000 Gain WDR70 Cervical squamous cell carcinoma
27 199384 5 38500000 42400000 Gain NUP155 Cervical squamous cell carcinoma
28 199385 5 38500000 42400000 Gain OXCT1 Cervical squamous cell carcinoma
29 199684 5 42400000 45800000 Gain CCL28 Cervical squamous cell carcinoma
30 199685 5 42400000 45800000 Gain FBXO4 Cervical squamous cell carcinoma
31 199686 5 42400000 45800000 Gain PAIP1 Cervical squamous cell carcinoma
32 199689 5 42400000 47700000 Gain ZNF131 Cervical squamous cell carcinoma
33 199835 5 4400000 6000000 Gain KIAA0947 Cervical squamous cell carcinoma
34 202451 5 8200000 15100000 Gain CCT5 Cervical squamous cell carcinoma
35 202452 5 8200000 15100000 Gain DAP Cervical squamous cell carcinoma
36 202454 5 8200000 15100000 Gain MARCH-VI Cervical squamous cell carcinoma
37 202462 5 8200000 23300000 Gain ZFYVE16 Cervical squamous cell carcinoma
38 202464 5 8200000 45800000 Gain OSRF Cervical squamous cell carcinoma

Expression for Cervical Squamous Cell Carcinoma

LifeMap Discovery
Genes differentially expressed in tissues of Cervical Squamous Cell Carcinoma patients vs. healthy controls: 35 (show all 33)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1 CRNN cornulin Uterus - 5.62 0.000
2 KRT1 keratin 1, type II Uterus - 5.32 0.000
3 UPK1A uroplakin 1A Uterus - 4.79 0.000
4 MAL mal, T-cell differentiation protein Uterus - 4.73 0.000
5 KRT4 keratin 4, type II Uterus - 4.45 0.000
6 SPRR3 small proline-rich protein 3 Uterus - 4.43 0.000
7 DSG1 desmoglein 1 Uterus - 4.27 0.000
8 CDKN2A cyclin-dependent kinase inhibitor 2A Uterus + 4.21 0.000
9 CRISP3 cysteine-rich secretory protein 3 Uterus - 4.13 0.000
10 CRCT1 cysteine-rich C-terminal 1 Uterus - 3.92 0.000
11 SPINK5 serine peptidase inhibitor, Kazal type 5 Uterus - 3.67 0.000
12 SLURP1 secreted LY6/PLAUR domain containing 1 Uterus - 3.54 0.000
13 APOC1 apolipoprotein C-I Uterus + 3.53 0.000
14 HOPX HOP homeobox Uterus - 3.51 0.000
15 EDN3 endothelin 3 Uterus - 3.48 0.000
16 FANCI Fanconi anemia, complementation group I Uterus + 3.42 0.000
17 SYNGR3 synaptogyrin 3 Uterus + 3.41 0.000
18 CRYAB crystallin, alpha B Uterus - 3.39 0.000
19 KRT13 keratin 13, type I Uterus - 3.35 0.004
20 MCM5 minichromosome maintenance complex component 5 Uterus + 3.31 0.000
21 ALOX12 arachidonate 12-lipoxygenase Uterus - 3.26 0.000
22 PPP1R3C protein phosphatase 1, regulatory subunit 3C Uterus - 3.23 0.000
23 SCEL sciellin Uterus - 3.19 0.000
24 NTS neurotensin Uterus + 3.19 0.006
25 NUSAP1 nucleolar and spindle associated protein 1 Uterus + 3.17 0.000
26 IVL involucrin Uterus - 3.14 0.000
27 IL1R2 interleukin 1 receptor, type II Uterus - 3.14 0.000
28 CFD complement factor D (adipsin) Uterus - 3.13 0.000
29 SOSTDC1 sclerostin domain containing 1 Uterus - 3.08 0.000
30 ESR1 estrogen receptor 1 Uterus - 3.06 0.000
31 PAMR1 peptidase domain containing associated with muscle regeneration 1 Uterus - 3.06 0.000
32 ENDOU endonuclease, polyU-specific Uterus - 3.04 0.000
33 HOXC6 homeobox C6 Uterus + 3.01 0.000
Search GEO for disease gene expression data for Cervical Squamous Cell Carcinoma.

Pathways for Cervical Squamous Cell Carcinoma

GO Terms for Cervical Squamous Cell Carcinoma

Cellular components related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.47 CDH1 CDKN2A DAPK1 DNAJC9 EGFR KRT17

Biological processes related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 regulation of apoptotic process GO:0042981 9.76 DAPK1 SKP2 TP53 TP63
2 epidermis development GO:0008544 9.67 EGFR KRT17 TP63
3 positive regulation of transcription, DNA-templated GO:0045893 9.63 CDH1 CDKN2A EGFR SOX2 TP53 TP63
4 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.48 TP53 TP63
5 viral entry into host cell GO:0046718 9.43 HLA-DRB1 SERPINB3
6 Ras protein signal transduction GO:0007265 9.43 CDKN2A RASSF1 TP53
7 regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043281 9.4 SOX2 TP63
8 replicative senescence GO:0090399 9.37 CDKN2A TP53
9 mitotic G1 DNA damage checkpoint GO:0031571 9.32 TP53 TP63
10 cell cycle arrest GO:0007050 9.26 CDKN2A RASSF1 SOX2 TP53
11 protein tetramerization GO:0051262 8.8 HLA-DRB1 TP53 TP63

Molecular functions related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 MHC class II receptor activity GO:0032395 8.96 HLA-DRB1 KRT17
2 virus receptor activity GO:0001618 8.62 HLA-DRB1 SERPINB3

Sources for Cervical Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....